A Pilot Study for Quantifying New Heart Muscle Cells

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after birth, but the precise timing of this decrease and how this decrease is altered in heart disease are uncertain. The investigators will use an innovative approach to quantify cellular heart regeneration in pediatric patients, an appropriate population for determining this decline as well as the potential for reactivating heart muscle regeneration. The study has now been registered on ClinicalTrials.gov, despite its initiation on July 23, 2015, as registration was not mandated at the original study site, the University of Pittsburgh Medical Center. However, following the transfer of the study to Weill Cornell Medicine, adherence to institutional requirements necessitated its registration on ClinicalTrials.gov.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 month
Maximum Age: 1
Healthy Volunteers: f
View:

• Patients at 30 days of age to 1 year of age undergoing scheduled elective cardiac surgery will be eligible for study inclusion.

• The investigators will recruit patients at 30 days of age to 1 year of age with those types of heart disease whose surgical approach has a high probability of myocardial resection.

• Diagnosis of ToF/PS or other types of heart disease that have a high likelihood of requiring surgery that involves routine resection of myocardium that becomes available for research

Locations
United States
New York
Weill Cornell Medicine
RECRUITING
New York
Contact Information
Primary
Rashida Blackwood, BS, MPH
rab4029@med.cornell.edu
646-962-9036
Time Frame
Start Date: 2015-07-23
Estimated Completion Date: 2027-03-01
Participants
Target number of participants: 30
Treatments
Experimental: N15-thymidine
Study participants will receive thymidine preparations for pre-defined blocks of time prior to the scheduled routine resection of myocardium.
Sponsors
Collaborators: California Institute of Technology, National Heart, Lung, and Blood Institute (NHLBI)
Leads: Weill Medical College of Cornell University

This content was sourced from clinicaltrials.gov